Glaxos Eosinophilic Asthma Drug Nucala Wins CHMP Backing – Zacks.com


BioPharma Dive

Glaxos Eosinophilic Asthma Drug Nucala Wins CHMP Backing
Zacks.com
In the U.S., the drug is approved for both COPD and asthma. We note that Glaxo has a collaboration agreement with Theravance for Relvar/Breo Ellipta and Anoro Ellipta (COPD). Relvar/Breo Ellipta generated sales of £94 million in the first half of 2015.
After bad news on Breo, Glaxo's monthly asthma drug wins an EU recBioPharma Dive

all 2 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.